Contributions
Abstract: PB1939
Type: Publication Only
Background
Chronic myeloid leukemia (CML) is a disease frequently diagnosed during routine examination or blood tests and patients may remain asymptomatic for many years. Recently the standard therapy is imatinib mesylate which provides both hematological, cytogenetic and molecular remission. Second generation tyrosine kinase inhibitors (TKIs) are effective in the first line therapy but often used in resistant/intolerant patients. Treatment requires tight compliance and regular blood checks. The patient’s lifetime treatment as well as regular controls affect the quality of life. Although a good quality of life with imatinib has been shown in many studies, generic imatinib is used in many countries and the data about second generation TKIs are scarce.
Aims
The aim of this study was to evaluate the quality of life of CML patients who are treated with tyrosine kinase inhibitors (generic imatinib, dasatinib and nilotinib).
Methods
A hundred and twenty patients and a healthy control group (n=20) were included after obtaining written informed consent. EORTC QLQ-CML24 and EORTC QLQ-C30 (version 3.0) scales were used to assess the quality of life. Mean age of the patients was 55±14.4 years and 68 (56%) of the patients were female. The mean duration of illness during the questionnaire was 6.7 ± 4.5 years. Imatinib group included 72, nilotinib group included 25 and dasatinib group included 23 CML patients.
Results
Scale of satisfaction with the care received and the scale of satisfaction with the amount of information received in imatinib group were lower than dasatinib group (p=0.007). Scale of insomnia in nilotinib grup was lower than imatinib group (p=0.027). No difference was found between imatinib, nilotinib, dasatinib groups and healthy controls for all other scales in the questionnaire.
Conclusion
The quality of life in CML patients under generic imatinib, nilotinib and dasatinib were evaluated in this study. The results give information about the quality of life with generic imatinib which is used in the first line therapy of CML in many countries and add new data on the quality of life with second generation TKIs. According to the results obtained it can be concluded that the quality of life is mostly similar with healthy controls and also similar between second generation TKIs.
Session topic: 8. Chronic myeloid leukemia - Clinical
Keyword(s): Chronic myeloid leukemia, Quality of Life, Side effects, Tyrosine kinase inhibitor
Abstract: PB1939
Type: Publication Only
Background
Chronic myeloid leukemia (CML) is a disease frequently diagnosed during routine examination or blood tests and patients may remain asymptomatic for many years. Recently the standard therapy is imatinib mesylate which provides both hematological, cytogenetic and molecular remission. Second generation tyrosine kinase inhibitors (TKIs) are effective in the first line therapy but often used in resistant/intolerant patients. Treatment requires tight compliance and regular blood checks. The patient’s lifetime treatment as well as regular controls affect the quality of life. Although a good quality of life with imatinib has been shown in many studies, generic imatinib is used in many countries and the data about second generation TKIs are scarce.
Aims
The aim of this study was to evaluate the quality of life of CML patients who are treated with tyrosine kinase inhibitors (generic imatinib, dasatinib and nilotinib).
Methods
A hundred and twenty patients and a healthy control group (n=20) were included after obtaining written informed consent. EORTC QLQ-CML24 and EORTC QLQ-C30 (version 3.0) scales were used to assess the quality of life. Mean age of the patients was 55±14.4 years and 68 (56%) of the patients were female. The mean duration of illness during the questionnaire was 6.7 ± 4.5 years. Imatinib group included 72, nilotinib group included 25 and dasatinib group included 23 CML patients.
Results
Scale of satisfaction with the care received and the scale of satisfaction with the amount of information received in imatinib group were lower than dasatinib group (p=0.007). Scale of insomnia in nilotinib grup was lower than imatinib group (p=0.027). No difference was found between imatinib, nilotinib, dasatinib groups and healthy controls for all other scales in the questionnaire.
Conclusion
The quality of life in CML patients under generic imatinib, nilotinib and dasatinib were evaluated in this study. The results give information about the quality of life with generic imatinib which is used in the first line therapy of CML in many countries and add new data on the quality of life with second generation TKIs. According to the results obtained it can be concluded that the quality of life is mostly similar with healthy controls and also similar between second generation TKIs.
Session topic: 8. Chronic myeloid leukemia - Clinical
Keyword(s): Chronic myeloid leukemia, Quality of Life, Side effects, Tyrosine kinase inhibitor